Table 2.
Association between APP status and clinicopathological parameters in 84 ER‐positive breast carcinomas
| APP status | P‐value | ||
|---|---|---|---|
| + (n = 45) | − (n = 39) | ||
| Age† (years) | 54.6 ± 3.4 | 57.7 ± 4.0 | 0.24 |
| Menopausal status | |||
| Premenopausal | 17 (20%) | 13 (15%) | 0.67 |
| Postmenopausal | 28 (33%) | 26 (31%) | |
| Stage | |||
| I | 12 (14%) | 19 (22%) | 0.17 |
| II | 23 (28%) | 15 (19%) | |
| III | 6 (12%) | 4 (11%) | |
| IV | 4 (9.3%) | 1 (2.6%) | |
| Pathological T factor (pT) | |||
| pT1 | 17 (20%) | 23 (27%) | 0.05 |
| pT2–4 | 28 (33%) | 16 (19%) | |
| Lymph node metastasis | |||
| Positive | 22 (26%) | 12 (14%) | 0.09 |
| Negative | 23 (27%) | 27 (32%) | |
| Distant metastasis | |||
| Positive | 4 (4.8%) | 1 (1.2%) | 0.22 |
| Negative | 41 (49%) | 38 (45%) | |
| Histological grade | |||
| 1 (well) | 11 (13%) | 13 (15%) | 0.07 |
| 2 (moderate) | 22 (26%) | 23 (27%) | |
| 3 (poor) | 12 (14%) | 3 (3.6%) | |
| PR status | |||
| Positive | 33 (39%) | 28 (33%) | 0.87 |
| Negative | 12 (14%) | 11 (13%) | |
| AR status | |||
| Positive | 36 (43%) | 28 (33%) | 0.38 |
| Negative | 9 (11%) | 11 (13%) | |
| AR LI† (%) | 39.8 ± 8.7 | 22.6 ± 5.8 | 0.002* |
| HER2 status | |||
| Positive | 6 (7.1%) | 2 (2.4%) | 0.29 |
| Negative | 39 (46%) | 37 (44%) | |
| Ki‐67 LI† (%) | 20.6 ± 5.2 | 11.0 ± 2.7 | 0.002* |
*P‐values less than 0.05 were considered significant. †Data are presented as mean ± SEM. All other values represent the number of cases and percentage. APP, amyloid precursor protein; AR, Androgen receptor; ER, estrogen receptor; PR, progesterone receptor.